Unlocking a New Era in Antiviral Drug Discovery

Phyto42 is the world's first company to tackle some of the most challenging viral threats by harnessing the potential of mannose-binding lectins (MBLs)—a class of proteins with remarkable specificity for sugar molecules present on the viral surface.

We utilize cutting-edge antiviral solutions, integrating artificial intelligence with groundbreaking science, coupled with in vitro and in vivo confirmation.

We are at the forefront of innovation, bringing together a team of experts passionate about combating viral infections using advanced AI technologies and a unique understanding of glycosylation.

Beyond identifying candidates, our team develops and validates our revolutionary antiviral therapeutics to deliver significantly more value.

Our Approach

Harnessing Mannose-Binding Lectins

Plant-based mannose-binding lectins (MBLs) have demonstrated a profound ability to target specific carbohydrate structures on glycosylated viruses. Unlike conventional antibody approaches, MBLs offer a fresh perspective, providing high affinity, multivalency, and reduced potential for viral escape mutations.

AI-Powered Drug Discovery

Our AI-driven drug discovery platform is the cornerstone of our approach. By utilizing state-of-the-art machine learning algorithms, we analyze vast amounts of biological data to identify promising MBL-based antiviral compounds. This approach accelerates the drug discovery process, allowing for the rapid development of effective antiviral therapeutics.

Key Advantages

High Affinity and Multivalency

MBLs possess multiple binding sites, allowing for a multivalent interaction with the glycosylated viral surface. This multivalency enhances the binding affinity and avidity of MBLs towards the glycoproteins on the virus, potentially leading to a more robust and effective neutralization compared to monovalent antibody binding.

Limited Potential for Viral Escape Mutations

Viruses can mutate and escape antibody recognition by modifying their protein epitopes. In contrast, targeting carbohydrate structures with MBLs is less prone to escape mutations since the glycosylation patterns are often vital for the virus's structure and function. Our broad-spectrum approach reduces the likelihood of the virus evolving to evade MBL recognition.

Complementary to Existing Therapies

MBLs can be used in conjunction with conventional antibody-based therapies, creating synergistic opportunities. The combined approach ensures a broader spectrum of antiviral activity by targeting different protein epitopes on the target virus, potentially enhancing treatment efficacy.

Join Our Revolution

Join us in the pursuit of a safer, healthier world. Our team is committed to advancing antiviral research through cutting-edge technology and first principles thinking. Stay tuned as we work to develop novel antiviral therapeutics based on the powerful MBL approach.

Reach out to learn more about our work, research, and commitment to revolutionize antiviral drug discovery using AI and plant-based MBLs. Together, we can make a difference in the fight against viral infections.

Contact

team@phyto42.health

Page updated

Report abuse